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INTRODUCTION
Progressive forms of chronic kidney disease are invariably associated with tubulointerstitial fibrosis (TIF), resulting in an ongoing loss of normal tissue structure and renal function that can lead to endstage renal disease (1) (2) (3) . It is well established that progressive TIF is exacerbated by multiple mediators including growth factors, metabolic toxins, and stress molecules (4) (5) (6) . Among them, transforming growth factor- (TGF-1) has been recognized as a key mediator in the pathogenesis of TIF (2, 7, 8) .
TGF-1 has a broad spectrum of biological actions in a wide variety of cell types, including renal tubular epithelial cells (TECs) (9, 10) . TGF-1 initiates its cellular actions across multiple cell types by binding with the TGF- type II receptor, which activates the TGF- type I receptor (TRI), resulting in the phosphorylation of Smad2/3 (11, 12) . The activated Smad complex then translocates into the nucleus and regulates the transcription of human profibrotic genes such as type I collagen (COL1A1) (13) , -smooth muscle actin (SMA) (14) , and Snail (SNAIL1) (15) .
Although Smad3 has been suggested to be a key transcription factor activated in response to many fibrogenic mediators, knockout of SMAD3 can cause autoimmune disease (16, 17) . No specific treatment is currently available to attenuate renal fibrogenesis and preserve organ function. Therefore, alternative approaches to inhibiting the TGF-/Smad pathway could be of importance in suppressing renal fibrosis without impairing the immune system.
Long noncoding RNAs (lncRNAs) are a heterogeneous class of long [>200 nucleotides (nt)] transcripts without protein-coding potential (18) . It is evident that lncRNAs have a wide range of biological functions, and their aberrant expression has been associated with diverse pathological settings, including cancer, metabolic, and cardiovascular diseases (19) (20) (21) . Emerging evidence has shown that lncRNAs may play a critical role in the pathogenesis of kidney diseases (22) , and functional lncRNAs regulating renal inflammation and mitochondrial bioenergetics have been recently identified (23, 24) . However, most of these studies were conducted using mouse lncRNAs. There are a limited number of studies on the functions of lncRNAs in the human kidney. Unlike other noncoding RNAs such as microRNAs and small nucleolar RNAs, which can exhibit high degrees of conservation across diverse species, lncRNAs often lack strong conservation (25, 26) . Furthermore, the biological roles of lncRNAs in regulating human TIF remain elusive, and more detailed studies are needed to unravel the molecular functions of lncRNAs in this setting.
Here, we investigated the potential role of lncRNAs involved in the progression of renal fibrosis and their underlying mechanisms. We identified a kidney-enriched TGF-/Smad3-interacting lncRNA, which we called lnc-TSI, that inhibited renal fibrogenesis through negative regulation of the TGF-/Smad pathway. This discovery adds to our understanding of the complex regulation of TGF-/ Smad signaling and provides a potential new therapeutic target for renal fibrosis.
RESULTS

Lnc-TSI is expressed in human TECs and is regulated by TGF-1 via a SMAD3-dependent mechanism
TGF-1/Smad signaling plays a critical role in the pathogenesis of TIF (2, 7, 8) . To identify lncRNAs that are potentially involved in the TGF-/Smad pathway, we first searched for lncRNA expression in TGF-1-stimulated human TECs (HK2 and HKC8 cells) using microarrays. We found that nine lncRNAs were up-regulated and two were down-regulated by more than fivefold (table S1). Through microarray profiling (Fig. 1A) , we identified lnc-TSI as the most upregulated lncRNA upon TGF-1 stimulation. Lnc-TSI was located at human chromosome 21 and was poorly conserved across species, as a clear orthologous counterpart could not be identified in the mouse genome via BLAST (Basic Local Alignment Search Tool). Northern blots and quantitative reverse transcription polymerase chain reaction (qRT-PCR) confirmed that lnc-TSI was constitutively expressed in human TECs and was up-regulated after TGF-1 stimulation (Fig. 1, B and C, and fig. S1A ). The expression of lnc-TSI in response to TGF-1 was dose-and time-dependent ( fig. S1 , B and C). Fluorescence in situ hybridization (FISH) demonstrated that lnc-TSI localized primarily to the cytoplasm of TECs (Fig. 1D ), which we verified by RT-PCR of the nuclear and cytoplasmic fractionations (Fig. 1E) .
To further determine the tissue specificity of lnc-TSI, we examined the expression of lnc-TSI in cultured cells of other epithelial parenchymal tissues in the presence or absence of TGF-1. Expression of lnc-TSI was low in human liver and lung cells, either with or without TGF-1, compared to that in TECs (Fig. 1F) . Lnc-TSI expression, as determined by in situ hybridization and RT-PCR, was up-regulated in human fibrotic kidney but not in fibrotic liver or lung (fig. S1, D and E). In kidney, lnc-TSI was expressed predominantly in the cytoplasm of proximal TECs and was up-regulated upon TGF-1 stimulation in vitro ( fig. S1 , F and G).
In the UCSC (University of California Santa Cruz) Genome Browser (27), we found lnc-TSI labeled as AP000695.6 or ENST00000429588.1. To determine the exact sequence of lnc-TSI, we performed 5′ and 3′ rapid amplification of complementary DNA ends (RACE) and found that lnc-TSI was a 941-nt lncRNA (Fig. 1G, fig. S1H , and data file S1). Lnc-TSI did not have a representative protein-coding open reading frame (ORF) longer than 300 nt according to ORF Finder (28) . As lnc-TSI expression was up-regulated by TGF-1, we investigated the role of SMAD2 and SMAD3, key factors in TGF-1 pathway, in lnc-TSI transcription. The expression of lnc-TSI decreased when SMAD3 was silenced with small interfering RNAs (siRNAs; Fig. 1H ). SMAD2 knockdown did not affect the expression of lnc-TSI (Fig. 1H  and fig. S1 , J and K), suggesting that the transcription of lnc-TSI was SMAD3-dependent.
Next, we performed chromatin immunoprecipitation (ChIP) analysis with an anti-SMAD3 antibody to determine whether SMAD3 could bind to the lnc-TSI promoter. According to JASPAR, a database of transcription factor binding profiles (29) , there are two predicted potential SMAD3-binding sites in the promoter region of lnc-TSI [−1321 to −1330 base pairs (bp) and −1766 to −1776 bp in human genome build hg38]. Our ChIP analysis demonstrated the interaction between SMAD3 and promoter region of lnc-TSI (−1321 to −1330 bp), indicating that lnc-TSI is a transcriptional target of SMAD3 (Fig. 1I ). To confirm, we cloned the promoter region between −1 and −2000 bp into a pGL3-enhancer vector. A luciferase reporter assay demonstrated As a control, an equivalent amount of phosphate-buffered saline (PBS) was added to the culture medium. Data are expressed as means ± SD of three independent experiments in (C), (H) to (J), and (L). Student's t test and one-way analysis of variance (ANOVA) were used for comparison between two groups and multiple groups, respectively. ns, not significant. that silencing SMAD3, but not SMAD2, reduced lnc-TSI promoter activity (Fig. 1J) . We further constructed a series of pGL3 reporter plasmids containing a mutant or wild-type region between −1216 to −1225 bp and −1321 to −1330 bp (Fig. 1K) . Mutation of the SMAD3-binding site (−1321 to −1330 bp) reduced luciferase activity, whereas mutation of the promoter sequence downstream of the SMAD3-binding site (−1216 to −1225 bp) did not influence the transcriptional activity (Fig. 1L) . These data suggest that Smad3 binds with the promoter of lnc-TSI and up-regulates the expression of lnc-TSI.
lnc-TSI inhibits TGF-1-induced SMAD3 phosphorylation in human TECs
To determine the role of lnc-TSI in regulating TGF-/Smad signaling, we knocked down lnc-TSI in HK2 or HKC8 cells by siRNA or lentivirus carrying lnc-TSI short hairpin RNAs (shRNAs). Real-time PCR showed that both methods efficiently reduced lnc-TSI expression in HK2 or HKC8 cells in the presence or absence of TGF- stimulation ( fig. S2 , A to C).
We ectopically expressed lnc-TSI in human TECs by transfecting the cells with pcDNA3.1 vector carrying the full-length sequence of lnc-TSI (fig. S2, D and E). Knocking down lnc-TSI increased TGF-1-induced SMAD3 phosphorylation without affecting SMAD2 phosphorylation ( Fig. 2A) . Transcription of SMAD3 and expression of SMAD4 and SMAD7 were not affected by either silencing or overexpressing lnc-TSI ( fig. S2, F and G) . Conversely, overexpression of lnc-TSI inhibited SMAD3, but not SMAD2, phosphorylation in HK2 cells (Fig. 2B) .
Translocation of Smad complexes into nuclei is a crucial step of TGF- signaling (11) . We fractionated the nuclei and cytoplasm of HK2 cells to investigate Smad nuclear translocation. Upon TGF-1 stimulation, knocking down lnc-TSI enhanced SMAD3, SMAD2, and SMAD4 nuclear translocation (Fig. 2C and fig. S2H ), whereas overexpression of lnc-TSI inhibited the translocation of these Smads into nuclei (Fig. 2D and fig. S2I ). Immunofluorescence staining confirmed that forced expression of lnc-TSI in HK2 cells abrogated TGF-1-induced SMAD3 nuclear translocation, and silencing lnc-TSI notably enhanced the translocation (Fig. 2E) . Furthermore, overexpression of lnc-TSI substantially decreased TGF-1-induced expression of SMAD3 target genes, including SNAIL1, COL1A1, and SMA (Fig. 2F) , whereas knocking down lnc-TSI enhanced their expression (Fig. 2G) . We validated these effects of lnc-TSI on the phosphorylation of SMAD3 and downstream responses using CRISPR-Cas9 ( fig. S3 ). These data suggest that lnc-TSI negatively regulates the TGF-/Smad3 pathway by specifically inhibiting the phosphorylation and subsequent nuclear translocation of SMAD3.
lnc-TSI binds to the MH2 domain of SMAD3 and blocks the interaction between TRI and SMAD3
We next explored the molecular mechanism underlying lnc-TSIinduced inhibition of SMAD3 phosphorylation. To identify potential lnc-TSI-interacting proteins, we performed RNA pull-down assays in vitro with biotinylated lnc-TSI, followed by mass spectrometry. In total, we identified seven proteins that associated with lnc-TSI (table S2) . Among them, three (SMAD3, -tubulin, and -tubulin) were confirmed to bind lnc-TSI by RNA pull-down (Fig. 3 , A to C) and RNA immunoprecipitation (RIP; fig. S4 , A and B). Other TGF- signaling-related proteins, such as SARA, TRI, SMAD2, SMAD4, and SMAD7, were not bound with lnc-TSI (Fig. 3C) . Consistent with this, a RIP assay showed that immunoprecipitation of SMAD3 or FLAGtagged SMAD3, but not other TGF- signaling-related proteins, retrieved lnc-TSI upon TGF-1 stimulation ( fig. S4B ). In addition, lnc-TSI FISH followed by immunofluorescence of SMAD3 demonstrated colocalization of lnc-TSI with SMAD3 in the cytoplasm of HK2 cells treated with TGF-1 (Fig. 3D) .
Although -and -tubulin can bind with lnc-TSI, knocking down these proteins did not affect the TGF-1-induced SMAD3 phosphorylation ( fig. S4 , C and D), suggesting that -and -tubulin did not affect the regulatory effect of lnc-TSI. Knocking down or overexpressing lnc-TSI did not affect the mRNA expression of the genes neighboring lnc-TSI ( fig. S4 , E and F).
To determine the nucleotide sequence of lnc-TSI that binds SMAD3, we prepared a series of lnc-TSI deletion mutants. As shown in Fig. 3G ), suggesting that stem-loops A and B were sites where lnc-TSI bound with SMAD3. To determine the precise binding sites of SMAD3 with lnc-TSI, we generated full-length or truncated SMAD3 constructs (Fig. 3H) . RIP ( Fig. 3I and fig. S4G ) and RNA pull-down assays (Fig. 3J ) demonstrated that lnc-TSI bound to the MH2 domain of SMAD3, a recognized binding domain of the cytoplasmic tail of TRI (12) .
Coimmunoprecipitation of SMAD3 or TRI with TRI-interacted proteins (SARA or SMAD2) demonstrated that knocking down lnc-TSI enhanced the interaction between SMAD3 and TRI but did not change the interaction between SMAD3 and SARA or SMAD2 and TRI ( Fig. 3K and fig. S4H ). Although overexpression of lnc-TSI hindered the interaction between TRI and SMAD3 in a dosedependent manner, it did not influence the interaction between SMAD3 and SARA, TRI, or SMAD2 ( 
Ectopic expression of human lnc-TSI in mouse TECs inhibits TGF-/Smad signaling
As mouse proximal tubular epithelial cells (mTECs) do not express lnc-TSI, we therefore evaluated whether ectopic expression of human lnc-TSI in mTECs may affect TGF-1/Smad signaling in these cells. Human lnc-TSI was efficiently transfected into mTECs (Fig. 4 , A to C). Transfection of lnc-TSI into mTECs suppressed TGF-1-induced phosphorylation of Smad3 without affecting Smad2 phosphorylation ( Fig. 4D ) and attenuated the expression of profibrotic genes downstream of Smad3 at both mRNA and protein levels (Fig. 4 , E and F).
The protein sequence of Smad3 is highly conserved and identical between human and mouse. An RNA pull-down assay indicated that lnc-TSI could bind to mouse Smad3 (Fig. 4G) . A RIP assay confirmed that mouse Smad3 could retrieve human lnc-TSI transfected into mTECs (Fig. 4H) . Transfection of lnc-TSI in mTECs inhibited the interaction of Smad3 with TRI in a dose-dependent manner but did not affect the interaction of Sara or Smad2 with TRI (Fig. 4I ). 
Delivery of human lnc-TSI alleviates renal fibrosis in mouse UUO and ischemic reperfusion injury-induced TIF
We used unilateral ureteral obstruction (UUO) mice to further explore the role of lnc-TSI in the pathogenesis of TIF in vivo. Animals were treated via hydrodynamic-based injection of human lnc-TSI plasmid or vector 2 days before and after operation (Fig. 5A ). Northern blots of kidney homogenates (Fig. 5B ) and in situ hybridization in renal tissue (Fig. 5C ) demonstrated the efficacy of delivering human lnc-TSI into mouse kidneys. In situ hybridization of lnc-TSI in mouse kidneys showed that lnc-TSI was mainly expressed in cortical tubule cells, with a transfection rate of about 50% (and rare expression observed in liver or spleen) ( fig. S5 ). Ectopic expression of lnc-TSI substantially alleviated TIF in UUO mice, as shown by Masson staining and TIF index in the kidney (Fig. 5, D and E) . Mechanistically, the RIP analysis showed that Smad3 was coprecipitated with lnc-TSI in kidney homogenates from mice injected with lnc-TSI plasmid (Fig. 5F) . Moreover, the delivery of lnc-TSI inhibited Smad3 activation in the kidney and down-regulated the expression of its target profibrotic genes, including Sma, Col1a1, and Fn1, at both mRNA and protein levels (Fig. 5, G to J) . To confirm the anti-fibrotic effect of lnc-TSI, we also treated UUO mice with adeno-associated virus (AAV)-carrying human lnc-TSI 7 days before operation. The infection rate of tubular cells in the cortex by AAV was above 50%, and we observed improvement of TIF index in animals infected with AAV-carrying human lnc-TSI ( fig. S5, G to L) . Cell lysates from mTECs were immunoprecipitated with anti-TRI antibody, followed by immunoblotting using antibodies against TRI, Sara, Smad2, and Smad3. NB, Northern blotting. Forced expression of human lnc-TSI in mTECs transfected with pcDNA3.1-lnc-TSI decreased the interaction between mouse TRI and Smad3 in a dose-dependent manner. Data are expressed as means ± SD of three independent experiments. Student's t test and one-way ANOVAs were used to compare two groups and multiple groups, respectively.
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To highlight the therapeutic potential of TSI, we injected mice three times with lnc-TSI plasmid at different time points (days 3, 5, and 7) after UUO surgery. Treatment with AAV delivery of lnc-TSI ameliorated the established TIF in this model (Fig. 6, A to F) . Similarly, in a unilateral ischemic reperfusion injury (IRI)-induced renal fibrosis model, treatment with hydrodynamic-based injection of pcDNA3.1-lnc-TSI ameliorated IRI-induced renal fibrosis and improved renal function post-ischemia (Fig. 6, G to M) .
Intrarenal lnc-TSI is up-regulated and negatively correlates with renal fibrosis in patients with fibrotic kidney disease To evaluate the role of lnc-TSI in the pathogenesis of human TIF, we conducted a cross-sectional analysis for the association of lnc-TSI expression and TIF in a cohort of 58 patients with biopsy-proven immunoglobulin A (IgA) nephropathy (IgAN), a chronic kidney disease with the potential to progress to renal fibrosis. Characteristics of patients at time of diagnosis (initial biopsy) were shown in S3. Among these patients, 72% had renal tubulointerstitial injury at initial renal biopsy with Oxford MEST-T grade ≥ 1 and a median TIF index of 0.7. In situ hybridization of lnc-TSI (Fig. 7A) and RT-PCR ( fig. S1E) showed that normal human kidney (tissue adjacent to renal carcinoma) constitutively expressed lnc-TSI in TECs. Expression of lnc-TSI was obviously up-regulated in renal biopsy samples from patients with IgAN. We found that SMAD3 was expressed in almost all tubulars, whereas pSMAD3 expression was found only in some of the TECs. Higher expression of lnc-TSI was associated with weaker pSMAD3 expression (Fig. 7B) . Partial correlation analysis showed a significant negative association between renal lnc-TSI expression and TIF index after adjusting the confounders such as mean arterial blood pressure and urinary protein excretion (Fig. 7C) . Lnc-TSI expression levels in kidney were also negatively correlated with pSMAD3 expression in a partial correlation analysis (Fig. 7D) .
For the longitudinal study, 32 patients with IgAN were followed up and received repeat renal biopsies at a mean duration of 48 months. All of these patients were treated with renin-angiotensin system inhibitors, and 23 (72%) received prednisone for a length of time. The characteristics of these patients are presented in table S4. The median renal lnc-TSI expression score at initial biopsy was 15. After follow-up at a mean of 48 months, patients with lnc-TSI expression less than the median at the initial biopsy had a greater increase in their TIF index and Oxford MEST-T grade at the repeat biopsy (Fig. 7 , E and F) and more pronounced decline in renal function represented by estimated glomerular filtration rate (eGFR) compared to those with baseline lnc-TSI expression greater than or equal to the median (Fig. 7G) .
To confirm the effect of lnc-TSI in human TIF, we detected the expression of lnc-TSI in a cohort of patients with chronic tubulointerstitial disease induced by aristolochic acid or uric acid nephropathy, which are well known non-immuneassociated kidney diseases. The expression pattern of lnc-TSI in this cohort was comparable to that in IgAN patients ( fig. S6 ).
DISCUSSION
In this study, we identified an lncRNA that functioned as a negative regulator of the TGF-1/Smad3 pathway. Lnc-TSI reduced renal fibrogenesis in humanized mice and may serve as a potential therapeutic target.
Phosphorylation of Smad3 by TRI has been documented as a key initial event in the activation of the TGF-/Smad pathway. Although several proteins and molecules have been reported to regulate the interaction between TRI and Smads (33) (34) (35) , there remains a large gap in understanding the mechanism underlying the key event.
We provided several lines of evidence demonstrating that lnc-TSI is a regulator of the interaction between TRI and Smad3. The effect of lnc-TSI was independent of Smad7, a known classical inhibitor of TGF-/Smad signaling (36) (37) (38) . In our study, there was no interaction between lnc-TSI and Smad7 in RNA pull-down or RIP assays, and neither knocking down nor overexpressing lnc-TSI affected the expression of Smad7. Although both lnc-TSI and Smad7 act by specifically inhibiting the phosphorylation of Smad3, the The expression of renal lnc-TSI negatively correlated with pSMAD3 expression in a partial correlation analysis after adjusting for mean arterial blood pressure and urinary protein excretion. (E to G) Thirty-two patients with IgAN were followed up and received repeat renal biopsy at a mean duration of 48 months. Comparing to those with baseline renal lnc-TSI expression greater than or equal to the median, patients with lnc-TSI expression less than the median at the initial biopsy had a higher proportion showing an increase in Oxford MEST-T grade at the repeat biopsy. P values were calculated by the  2 test. (E) Those with lower expression of lnc-TSI at the initial biopsy also had a more pronounced increase in TIF index (F) and a more pronounced decline in eGFR (G). Data in (F) and (G) are presented as box-and-whisker plots to show quartiles (boxes) and range (whiskers). P values were calculated by Student's t test.
mechanisms of blocking the access of Smads to TRI are different. Lnc-TSI blocked this interaction by binding with the MH2 domain of Smad3, whereas Smad7 is known to act either by forming a stable complex with activated TRI or by causing degradation of TRI (38, 39) . Smad3 controlled lnc-TSI expression through binding with the promoter of lnc-TSI under TGF-1 stimulation, thereby upregulating expression of lnc-TSI in TECs. Therefore, in conditions with increased TGF-, such as inflammatory kidney disease, lnc-TSI may function as a negative regulator of the TGF-1/Smad pathway. The feedback loop formed among TGF-1, Smad3, and lnc-TSI is shown in fig. S7 . We found that lnc-TSI may play an important role in the pathogenesis of TIF. It is well accepted that TGF-1/Smad3 is a key pathway in the pathogenesis of TIF in both human and experimental animal kidney diseases (40) . Delivery of human lnc-TSI to mouse TECs decreased TGF-1-induced expression of profibrotic genes and improved renal fibrosis in the well-established UUOinduced chronic model of TIF (41) and IRI-induced TIF. As UUO is not meant to replicate human disease, we also tested lnc-TSI expression in patients with newly diagnosed IgAN, an inflammatory chronic kidney disease with the potential to progress to renal fibrosis. We found that expression of renal lnc-TSI was up-regulated in patients with IgAN. Lnc-TSI expression in patient kidneys negatively correlated with the severity of TIF. We also detected the expression of lnc-TSI in an additional cohort of patients with chronic tubulointerstitial disease induced by aristolochic acid or uric acid nephropathy. Consistently, the expression pattern of lnc-TSI in this cohort was comparable with that seen in IgAN. In patients who had received repeat renal biopsies, lower expression of renal lnc-TSI at initial kidney biopsy was associated with a more pronounced decline in renal function and an increase in TIF at repeat renal biopsy 4 years later, suggesting that kidney-enriched lnc-TSI may regulate human renal fibrogenesis. An alternative possibility is that less lnc-TSI is produced as tubular atrophy, and this may be a good marker for renal fibrosis progression. We observed that lnc-TSI was only induced in the fibrotic kidney but not in liver or lung. The tissue-specific expression of lncRNAs has been reported in previous studies (42) (43) (44) , with a recent study demonstrating that lncRNA Wisper controls cardiac fibrosis but not kidney fibrosis (45) .
There are limitations to this study. We were not able to investigate the role of lnc-TSI in a tubule-specific lnc-TSI transgenic mouse, which may yield more convincing evidence. Moreover, we were not able to test the effect of lnc-TSI by knocking down the lnc-TSI in vivo as it is not expressed in mouse kidneys. In addition, the two mouse models we used do not directly reflect human diseases resulting in fibrogenesis in the kidney, and renal fibrosis in these models was only established over the course of several days before therapeutic treatment with lnc-TSI. Further studies will be needed to see whether lnc-TSI can be therapeutically targeted in humans.
In conclusion, our study identified a kidney-enriched lncRNA that function as an endogenous inhibitor of TGF-1/Smad3 pathway and regulated renal fibrogenesis. These findings provide novel information for understanding the mechanisms underlying TGF-1-mediated tissue fibrosis. Our work hints at the possibility of a new therapeutic target to halt the most damaging process in kidney diseases, although this remains to be confirmed by future studies.
MATERIALS AND METHODS
Study design
The aim of this study was to identify and evaluate whether tissuespecific lncRNAs were potentially suitable as therapeutic targets for TGF-1-mediated renal fibrosis. Using microarray analysis and RT-PCR, we identified the most up-regulated lncRNA in kidney upon TGF-1 stimulation, which we named lnc-TSI. Using in situ hybridization and RT-PCR, we evaluated the tissue specificity of lnc-TSI expression in various types of cells from epithelial parenchymal tissues, in the presence or absence of TGF-1, and in human fibrotic tissues (kidney, lung, and liver). Loss-and gain-of-function experiments were performed in human TECs to test the role of lnc-TSI in the TGF--mediated fibrotic response in vitro. The lossof-function approach was validated using CRISPR-Cas9. To explore the molecular mechanism underlying lnc-TSI-induced inhibition of Smad3 phosphorylation, we performed RNA pull-down followed by mass spectrometry to identify lnc-TSI-associated proteins. RNA pull-down and RIP assays assessed the potential interaction of lnc-TSI with Smad3 or other Smads. Interaction between TRI and Smad3 or other TRI-associated proteins was determined by coimmunoprecipitation.
To examine the role of lnc-TSI in renal fibrosis in vivo, we chose UUO mice as a chronic model of TIF. Mice were randomly assigned to UUO and Sham operation groups. To test whether lnc-TSI may hold therapeutic potential in TIF, we conducted gain-of-function experiments by delivering human full-length lnc-TSI to UUO mice by hydrodynamic-based injection of an lnc-TSI-carrying plasmid or AAV9-carrying lnc-TSI. To test the effect of lnc-TSI on fibrosis, we performed hydrodynamic-based injection both 2 days before and 2 days after surgery, whereas AAV9 injection was conducted 7 days before surgery. To test a potential therapeutic effect of lnc-TSI, hydrodynamic-based injection of lnc-TSI was performed on days 3, 5, and 7 after UUO. Renal fibrosis was quantified by Masson's trichrome staining, and the extracellular matrix expression on kidney sections was scored by two pathologists in a blinded manner. All sample measurements were blinded.
To evaluate the role of lnc-TSI in the pathogenesis of human renal fibrosis, we conducted a cross-sectional analysis of the association between lnc-TSI expression and TIF in a cohort of 58 patients with biopsy-confirmed IgAN. Renal fibrosis in the biopsy samples was quantified by Masson's trichrome staining and scored by two pathologists in a blinded manner. Expression of lnc-TSI in the kidney biopsy samples was determined with in situ hybridization. Association between the levels of lnc-TSI expression and severity of TIF was analyzed with partial correlation analysis. For the longitudinal study, 32 patients with IgAN were followed up and received repeat renal biopsies at a mean of 48 months after initial biopsy. Patients were divided into two groups according to their median renal lnc-TSI expression at the initial biopsy (<15 and ≥15). Changes in the renal fibrosis index, Oxford MEST-T grade, and eGFR at follow-up were compared between the two groups. siRNA oligos and primers used in this study (table S5), deletion mutants (table S6) , and subject-level data for experiments with n < 20 (table S7) can be found in the Supplementary Materials. Cells were grown in Dulbecco's modified Eagle's medium (DMEM)/ Ham's F12 medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen). Human embryonic kidney (HEK) 293T cells (ATCC) were cultured in DMEM (Invitrogen) supplemented with 10% fetal bovine serum. These cells were cultured at 37°C in an atmosphere containing 5% CO 2 . Human immortalized podocytes AB8/13, a gift from M. Saleem's laboratory, were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (46) . The cells were cultured at 33°C and differentiated at 37°C in an atmosphere containing 5% CO 2 . In some experiments, cells were serum-starved overnight when they reached about 70% confluence and then incubated with indicated doses of recombinant TGF-1 (R&D Systems) or EGF (PeproTech) for various times as indicated.
Cell culture
Animal models UUO in mice
The UUO model was induced in male C57BL/6 mice (Guangdong Medical Animal Center, Guangzhou) when mice were at 6 to 8 weeks of age with body weight of 20 to 25 g, as previously described (47) . Briefly, the left ureter of mice was ligated under anesthesia with intraperitoneal injection of sodium pentobarbital, and the UUO kidney was harvested for analysis at the indicated number of days after surgery. Sham-operated mice were used as controls. IRI-induced TIF in mice IRI-induced TIF was performed in male C57BL/6 mice (Guangdong Medical Animal Center) at 6 to 8 weeks of age with body weight of 20 to 25 g, as previously described (48) , with minor modifications. Briefly, under general anesthesia by sodium pentobarbital, the left renal pedicle was clipped for 30 min using microaneurysm clamps (Fine Science Tools). After removal of the clamps, reperfusion of the kidneys was visually confirmed. The body temperature of the mice was maintained between 37° and 38°C by applying a temperaturecontrolled heating device. Ten days after the induction of IRI, the right kidney was surgically removed. Sham-operated mice were used as controls. All animal studies were approved by the Nanfang Hospital Animal Care Committee and were performed according to the institutional guidelines of Southern Medical University.
Human subjects
Cohort of patients with IgAN
A total of 58 patients with newly diagnosed, biopsy-confirmed primary IgAN [macroalbuminuria (urinary protein excretion > 0.3 g/ day) and eGFR > 60 ml/min per 1.73 m 2 , with or without hypertension] from Nanfang Hospital (Guangzhou, China) were included in our analysis. This cohort consisted of IgAN patients with low to moderate risk for disease progression at the time of diagnosis (49) . We excluded patients with cofounding diseases such as diabetes, liver disease, and infection, and those with nephrotic-range proteinuria (>3.5 g/day) at the time of diagnosis. No patients received any treatment before diagnostic renal biopsy. Clinical characteristics of the patients at initial biopsy are shown in table S3. Thirty-two patients received repeat renal biopsy at a mean of 48 months of followup. The clinical characteristics of the patients at baseline are presented in table S4. Cohort of patients with chronic tubulointerstitial disease A total of 15 patients with biopsy-proven chronic tubulointerstitial disease (12 cases caused by aristolochic acid and 3 by uric acid nephropathy) were included in the study. Clinical characteristics of the patients are shown in table S3. The observational clinical study was approved by the Institutional Review Board of the National Clinical Research Center for Kidney Disease (Guangzhou, China). The human samples used in the study were approved by the Board. All of the study participants provided written informed consent.
Gene delivery in an animal model
Hydrodynamic-based injection of lnc-TSI pcDNA3.1-human lnc-TSI or empty vector pcDNA3.1 (Invitrogen) was injected by intravenous injection, as previously described (50) . Briefly, 10 g of plasmid DNA was diluted in 1.6 ml of saline and injected via the tail vein within 10 s for each mouse.
AAV9 transduction of lnc-TSI
The full length of lnc-TSI was inserted into a pAV-MIR-GFP vector. After sequencing ensured accuracy of the vector, AAV (serotype 9) was packaged, purified, and titrated by Vigene Biosciences. AAV9 (1 × 10 12 copies) harboring either the lnc-TSI or the control sequence was injected through the left renal vein of mice (51) . Briefly, under general anesthesia, the left kidney of the mouse was exposed. The renal vein was clamped by microaneurysm clamp, and AAV particles diluted in 100 l of saline were injected into the vein using a 31-gauge needle. The clamp was removed 15 min after injection followed by suturing of the incision.
Statistical analysis
Continuous variables were expressed as means ± SD or median (interquartile range). Categorical variables were expressed as number (percentages). Data were tested for normality using KolmogorovSmirnov test, and variance homogeneity using Levene's test. For comparing normally distributed continuous variables, we used twotailed Student's t test or one-way ANOVA with a Tukey's post hoc test. For comparing variables that were not normally distributed, we used the Mann-Whitney U test. The  2 test was used for the comparison of categorical variables. Partial correlations analyzed the associations between lnc-TSI expression and the TIF index or pSmad3 expression, adjusting for mean arterial blood pressure and urinary protein excretion. P < 0.05 was considered statistically significant.
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